Samuel J. Reich - 29 Nov 2023 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Executive Chairman, Director
Signature
/s/ Samuel J. Reich
Issuer symbol
SABS
Transactions as of
29 Nov 2023
Net transactions value
+$9,842
Form type
4
Filing time
30 Nov 2023, 08:00:04 UTC
Previous filing
16 Mar 2023
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SABS Common Stock Purchase $9,842 +11,000 +5.3% $0.8947 219,001 29 Nov 2023 Direct F1, F2
holding SABS Common Stock 547,698 29 Nov 2023 Via Big Cypress Holdings LLC
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 11,000 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), acquired by the reporting person in an open market transaction.
F2 Includes 1,000 shares of Common Stock held jointly by the reporting person and the reporting person's spouse.